SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

SeaStar Medical Holding Corporation

SeaStar Medical is a medical device company developing novel cell-directed extracorporeal therapies to fight the life-threatening consequences of hyperinflammation.

SeaStar Medical

PRESS RELEASE: First Patient Enrolled in SeaStar Medical’s Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

Read the full release here: https://lnkd.in/ene8c5HJ

#pressrelease #medical #medicaldevices #clinicaltrials #medtech #ICU

SeaStar Medical is proud to announce our sponsorship of the inaugural season of the Critical Care Time (www.criticalcaretime.com) podcast by co-creators Nick Mark, MD (of ICU Onepager fame!) & Cyrus Askin, MD.

See the press release HERE: https://lnkd.in/enbP3puq

 #CritCareTime #ICU #OnePagerICU

At SeaStar Medical, we are fighting the effects of a dysregulated immune response. Here’s a closer look at how our novel Selective Cytopheretic Device (SCD) deactivates inflammatory neutrophils & monocytes to restore immune balance.

#MedDevice #ICU #immunesystem #medical

Learn how our Selective Cytopheretic Device (SCD) modulates immune effector cells responsible for a dysregulated immune response.

#MedTech #MedDevice #SCD #AKI #ICU

At SeaStar Medical, we are fighting the effects of a dysregulated immune response. Learn how this imbalance drives hyperinflammation and damage in acute kidney injury. More info at https://bit.ly/3PixGJE

#Hyperinflammation #AKI #ICU $ICU

SeaStar Medical to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21, 2023. Sign up now: https://lnkd.in/eTbbvsa3

Full Press Release: https://lnkd.in/eW5Da9e2
 
 #ICU #SeaStar #Hyperinflammation #CellDirectedTherapy #Kidney $ICU

SeaStar Medical is proud to support the ADQI Conference on Extracorporeal Therapies, June 9-12 in Vicenza, Italy

Learn more about ADQI's important initiatives at https://bit.ly/3Cpkrz6

#AKI #CriticalCare #ICU

Today our CMO, Dr. Kevin Chung, will be delivering "Novel Targets for Blood Purification - Pathogens, Endotoxins, Neutrophils, Oh My!" for the 7th Annual Southern California Kidney Symposium at 2PM PST - tune in to hear this exciting talk! https://lnkd.in/eRBGcSrK

#AKI #ICU $ICU

Hear from our very own Chief Medical Officer, Dr. Kevin Chung, on Novel Targets for Blood Purification this Friday June 9th at 2pm PST at the 7th Annual Southern California Kidney Symposium

Register now for this hybrid event: https://lnkd.in/eRBGcSrK

#AKI #ICU $ICU

	Dec '20	Dec '21	Dec '22	Dec '23
net income	-3.28M -	-4.60M 40.29%	-23.01M 400.72%	-26.23M 13.99%
depreciation and amortization
deferred income tax
stock based compensation	0.02 -	14K 87,499,900%	1.31M 9,264.29%	1.93M 47.22%
change in working capital	890K -	-680K 176.40%	2.55M 475.29%	2.88M 12.74%
accounts receivables			4K -	12K 200%
inventory	137K -	55K 59.85%	-4K 107.27%
accounts payables	225K -	-297K 232.00%	1.55M 621.21%	2.44M 57.95%
other working capital	528K -	-438K 182.95%	1.00M 329.22%	420K 58.17%
other non cash items	-3.19M -	148K 104.65%	11.36M 7,572.97%	11.14M 1.90%
net cash provided by operating activities	-5.57M -	-5.11M 8.22%	-7.79M 52.41%	-10.29M 31.96%
investments in property plant and equipment
acquisitions net
purchases of investments		-105.57M -
sales maturities of investments
other investing activites		105.57M -
net cash used for investing activites		-105.57M -
debt repayment	-300K -	-20K 93.33%	-78K 290%	-3.03M 3,784.62%
common stock issued	25K -		10.00M -	5.51M 44.87%
common stock repurchased
dividends paid
other financing activites	5.17M -	2.84M 45.09%	-2.59M 191.36%	1.87M 172.15%
net cash used provided by financing activities	4.89M -	2.82M 42.42%	7.33M 160.24%	10.41M 42.05%
effect of forex changes on cash		105.57M -
net change in cash	-680K -	-2.30M 237.79%	-463K 79.84%	129K 127.86%
cash at beginning of period	3.49M -	2.81M 19.50%	510K 81.83%	47K 90.78%
cash at end of period	2.81M -	510K 81.83%	47K 90.78%	176K 274.47%
operating cash flow	-5.57M -	-5.11M 8.22%	-7.79M 52.41%	-10.29M 31.96%
capital expenditure
free cash flow	-5.57M -	-5.11M 8.22%	-7.79M 52.41%	-10.29M 31.96%

COM:SEASTARMEDICAL

SeaStar Medical

Last Close

2.20

22/11 21:00

Market Cap

25.99M

Beta: -

Volume Today

141.03K

Avg: -

Preview